[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

About: Dotinurad

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Dotinurad (Urece) is a drug for the treatment of gout and hyperuricemia. It was developed by and approved for use in Japan in 2020. The drug is continuing clinical trials by Fortress Biotech and regulatory evaluation for approval in North America and Europe. Dotinurad acts as a selective urate reabsorption inhibitor that has uric acid lowering activity.

Property Value
dbo:abstract
  • Dotinurad (Urece) is a drug for the treatment of gout and hyperuricemia. It was developed by and approved for use in Japan in 2020. The drug is continuing clinical trials by Fortress Biotech and regulatory evaluation for approval in North America and Europe. Dotinurad acts as a selective urate reabsorption inhibitor that has uric acid lowering activity. (en)
  • ドチヌラド(英: Dotinurad、開発コードFYU-981)は、痛風、高尿酸血症の治療薬として持田製薬と富士薬品が共同開発した。尿酸再吸収の抑制による血中尿酸低下作用を持つ新規の薬剤で、選択的尿酸再吸収阻害薬(SURI; 英: Selective urate reabsorption inhibitor)、尿酸排泄促進薬に分類される。日本でユリス(英: URECE)として2020年1月に承認された。2019年10月現在、海外では開発されていない。 (ja)
dbo:alternativeName
  • Urece (en)
dbo:casNumber
  • 1285572-51-1
dbo:chEMBL
  • 4594446
dbo:drugbank
  • DB16145
dbo:fdaUniiCode
  • 305EB53128
dbo:kegg
  • D11071
dbo:pubchem
  • 51349053
dbo:thumbnail
dbo:wikiPageID
  • 68031245 (xsd:integer)
dbo:wikiPageLength
  • 5069 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1075450664 (xsd:integer)
dbo:wikiPageWikiLink
dbp:c
  • 14 (xsd:integer)
dbp:casNumber
  • 1285572 (xsd:integer)
dbp:chembl
  • 4594446 (xsd:integer)
dbp:chemspiderid
  • 59718651 (xsd:integer)
dbp:cl
  • 2 (xsd:integer)
dbp:drugbank
  • DB16145 (en)
dbp:h
  • 9 (xsd:integer)
dbp:iupacName
  • -methanone (en)
dbp:kegg
  • D11071 (en)
dbp:legalStatus
  • Rx-only (en)
dbp:n
  • 1 (xsd:integer)
dbp:o
  • 4 (xsd:integer)
dbp:pubchem
  • 51349053 (xsd:integer)
dbp:s
  • 1 (xsd:integer)
dbp:smiles
  • C1NCC3=CCCl (en)
dbp:stdinchi
  • 1 (xsd:integer)
dbp:stdinchikey
  • VOFLAIHEELWYGO-UHFFFAOYSA-N (en)
dbp:synonyms
  • FYU-981 (en)
dbp:tradename
  • Urece (en)
dbp:unii
  • 305 (xsd:integer)
dbp:wikiPageUsesTemplate
dcterms:subject
rdf:type
rdfs:comment
  • Dotinurad (Urece) is a drug for the treatment of gout and hyperuricemia. It was developed by and approved for use in Japan in 2020. The drug is continuing clinical trials by Fortress Biotech and regulatory evaluation for approval in North America and Europe. Dotinurad acts as a selective urate reabsorption inhibitor that has uric acid lowering activity. (en)
  • ドチヌラド(英: Dotinurad、開発コードFYU-981)は、痛風、高尿酸血症の治療薬として持田製薬と富士薬品が共同開発した。尿酸再吸収の抑制による血中尿酸低下作用を持つ新規の薬剤で、選択的尿酸再吸収阻害薬(SURI; 英: Selective urate reabsorption inhibitor)、尿酸排泄促進薬に分類される。日本でユリス(英: URECE)として2020年1月に承認された。2019年10月現在、海外では開発されていない。 (ja)
rdfs:label
  • Dotinurad (en)
  • ドチヌラド (ja)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License